An observational study in Gastric Cancer, RWS and PD-1 Immunotherapy, sponsored by Changzhi People's Hospital Affiliated to Changzhi Medical College. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-07-03.
Sponsored by Changzhi People's Hospital Affiliated to Changzhi Medical College · Observational
The purpose of this observational study is to evaluate the safety and efficacy of camrelizumab and apatinib in patients with advanced gastric cancer under real-life conditions, particularly in various subgroups of gastric cancer patients, with a view to providing information about the treatment modalities and efficacy of the treatment in real-life gastric cancer patients and to explore the possible predictive biomarkers of prognosis.Patients, who had both decided to be treated with camrelizumab or apatinib prior to enrollment, were entered into one of the following three cohorts at the discretion of the investigator, based on their disease stage and prior treatment
2,851 studies on the registry are indexed under Stomach Neoplasms; 864 are open to participants now.
This study's planned enrollment of 504 is above the median of 274 across 670 observational studies indexed under Stomach Neoplasms.
Browse Stomach Neoplasms studies →Changzhi People's Hospital Affiliated to Changzhi Medical College is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with advanced gastric cancer confirmed by pathology or histology
Exclusion Criteria:
First-line
Drug: Camrelizumab · Drug: apatinib · Drug: chemotherapy
Second-line
Drug: Camrelizumab · Drug: apatinib · Drug: chemotherapy
Third-line and above
Drug: Camrelizumab · Drug: apatinib · Drug: chemotherapy
200mg,iv,d1,Q2W/Q3W
250mg,qd
Standard treatment
Objective response rate
The percentage of subjects achieving complete or partial response in a real-world clinical setting.
Time frame: 24 months
Progression free survival
From date of admission until the date of first documented progression in the real-world setting or date of death from any cause, whichever came first, assessed up to 24 months.
Time frame: 24 months
Disease control rate
The percentage of subjects achieving complete response, partial response, or disease stability in a real-world clinical setting.
Time frame: 24 months
Overall survival
From date of admission until the date of death from any cause, assessed up to 24 months.
Time frame: 24 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changzhi People's Hospital Affiliated to Changzhi Medical College